Mobidiag

40 articles about Mobidiag

• Hologic Completes Acquisition of Mobidiag

  6/17/2021

  Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately $808 million.

• Mobidiag Receives CE-IVD Marking for Amplidiag® RESP-4 for Simultaneous Detection of COVID-19, Flu A, Flu B and RSV

  3/1/2021

  One single test determines the virus responsible for patient symptoms, guiding treatment decisions and rapid isolation strategy if required

• Mobidiag Receives Second Tranche of €25M Financing from European Investment Bank

  6/16/2020

  Second tranche of €10M from €25M growth capital loan signed with the European Investment Bank in May 2019

• Mobidiag Offers Complete Diagnostic Solution for the Detection of Novel Coronavirus Infections with Both PCR and Antibody Tests

  6/2/2020

  CE-IVD marked molecular diagnostic tests on the Novodiag® and Amplidiag® platforms for rapid detection of COVID-19 infections to support decisions for efficient patient isolation, treatment and release

• Novodiag® COVID-19, a Fully Automated Molecular Diagnostic Test from Mobidiag, Granted Emergency Use Authorization in Finland for Novel Coronavirus

  4/22/2020

  Real-time RT-PCR-based test enables fast, on demand and fully automated detection of early COVID-19 infections for rapid isolation and treatment guidance;

• Amplidiag® COVID-19 Molecular Diagnostic Test Granted Emergency Use Authorization in Finland for Novel Coronavirus

  4/14/2020

  Real-time PCR-based test enables high-throughput reliable detection of early COVID-19 infections for rapid isolation and treatment guidance

• Development of Novodiag® Assay for Safe and Easy Molecular Testing of Novel Coronavirus and Influenza Viruses

  2/10/2020

  Mobidiag Ltd. announces that it has initiated development of a Novodiag® molecular diagnostic test for the rapid and simultaneous detection of the novel coronavirus and influenza viruses.

• Mobidiag Secures Additional Funding from Business Finland for Rapid Sepsis Diagnostic Test

  1/7/2020

  Mobidiag Ltd. announces that it has been granted EUR 1.5 million additional funding from Business Finland for the continued development of a rapid diagnostic test for sepsis using Mobidiag’s Novodiag platform.

• Mobidiag Signs New International Agreements for Distribution of its Amplidiag® and Novodiag® Diagnostic Solutions

  10/29/2019

  Agreements signed in Poland, Ukraine, Romania and Israel, with more in discussions.

• New Novodiag® Stool Parasites Test Allows Rapid, Accurate and Cost-effective Molecular Testing for Gastrointestinal Infections

  10/9/2019

  Mobidiag Ltd. announces the CE-IVD marking of the Novodiag® Stool Parasites test, a comprehensive and cost-effective molecular diagnostic test for the detection of intestinal parasites directly from stool samples.

• Mobidiag Signs Exclusive Agreement With Pro Med Diagnostics for the Distribution of Amplidiag® and Novodiag® Diagnostic Solutions in Africa

  7/1/2019

  Agreement signed for South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya, Uganda

• Mobidiag announces launch of Automobi Molecular Diagnostics

  6/3/2019

  Joint venture between Mobidiag and Autobio Diagnostics will commercialise Novodiag® platform and selected infectious disease assays in the Greater China territory

• Investment Plan for Europe: Mobidiag Secures EUR 25 Million from EIB

  5/14/2019

  Funds will be used to accelerate the development and commercialisation of in vitro diagnostic solutions for infectious diseases.

• Mobidiag to Attend the 29th European Congress of Clinical Microbiology & Infectious Diseases in Amsterdam, the Netherlands

  3/19/2019

  Mobidiag will showcase its fast, reliable and cost-effective molecular diagnostic solutions

• Mobidiag Signs Multiple International Agreements for Distribution of Its Amplidiag® and Novodiag® Diagnostic Solutions

  2/25/2019

  Agreements signed in Greece, Latvia, Lithuania and Kuwait, with more in discussions

• Mobidiag Announces Completion of €10m Equity Investment from Autobio Diagnostics

  2/4/2019

  Proceeds from the €10m equity investment from Autobio will be used by Mobidiag to continue growing its product portfolio, accelerate the development of further assays for the Novodiag® system and enhance its manufacturing capabilities, as well as continuing to facilitate Mobidiag’s commercial expansion.

• New Novodiag® CarbaR+ Test Allows Rapid, Cost-Effective Molecular Testing for ‘Superbacteria’ and Associated Drug Resistance

  1/7/2019

  Mobidiag Ltd. announces the CE-IVD marking of Novodiag® CarbaR+.

• Mobidiag Release: Novodiag Launch, a New Diagnostic Solution for Infectious Diseases

  1/3/2018

  The new Novodiag solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results within a few hours.

• Mobidiag Announces Release Of Amplidiag Viral GE, A Multiplex PCR Test To Detect Gastrointestinal Viruses Directly From Stool Samples

  6/26/2017

• Mobidiag Extends Distribution Agreement With PerkinElmer To Offer Amplidiag Diagnostics Products In African Countries And Israel

  5/30/2017